1. Home
  2. GLBS vs LITS Comparison

GLBS vs LITS Comparison

Compare GLBS & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globus Maritime Limited

GLBS

Globus Maritime Limited

HOLD

Current Price

$2.15

Market Cap

35.0M

ML Signal

HOLD

LITS

Lite Strategy Inc.

N/A

Current Price

$1.11

Market Cap

40.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GLBS
LITS
Founded
2006
2000
Country
Greece
United States
Employees
N/A
4
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.0M
40.8M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
GLBS
LITS
Price
$2.15
$1.11
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
67.4K
386.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$24.03
N/A
Revenue Next Year
$13.92
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.95
52 Week High
$2.12
$3.03

Technical Indicators

Market Signals
Indicator
GLBS
LITS
Relative Strength Index (RSI) 68.96 44.79
Support Level $1.06 $0.95
Resistance Level N/A $1.16
Average True Range (ATR) 0.14 0.08
MACD 0.04 0.02
Stochastic Oscillator 100.00 57.45

Price Performance

Historical Comparison
GLBS
LITS

About GLBS Globus Maritime Limited

Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: